Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press20310.17650/2220-3478-2017-7-1-46-56REVIEWОБЗОРЫ ЛИТЕРАТУРЫIrinotecan in the treatment of colorectal cancer. A literature reviewИринотекан в лечении колоректального рака. Обзор литературыIvanovV. A.ИвановВ. А.
Russian Federation

Хирургическое отделение № 3 (онкопроктологии) Минздрава России; Россия, 115478 Москва, Каширское шоссе, 23

GordeevS. S.ГордеевС. С.
Russian Federation

Surgical Department No 3 (Coloproctology), 23 Kashirskoe Shosse, Moscow 115478, Russia

Хирургическое отделение № 3 (онкопроктологии) Минздрава России; Россия, 115478 Москва, Каширское шоссе, 23

ss.netoncology@gmail.comBaychorov,A. B.БайчоровА. Б.
Russian Federation

Surgical Department No 3 (Coloproctology), 23 Kashirskoe Shosse, Moscow 115478, Russia

Хирургическое отделение № 3 (онкопроктологии) Минздрава России; Россия, 115478 Москва, Каширское шоссе, 23

AlievV. A.АлиевВ. А.
Russian Federation

Surgical Department No 3 (Coloproctology), 23 Kashirskoe Shosse, Moscow 115478, Russia

Хирургическое отделение № 3 (онкопроктологии) Минздрава России; Россия, 115478 Москва, Каширское шоссе, 23

Kuz’michevD. V.КузьмичевД. В.
Russian Federation

Surgical Department No 3 (Coloproctology), 23 Kashirskoe Shosse, Moscow 115478, Russia

Хирургическое отделение № 3 (онкопроктологии) Минздрава России; Россия, 115478 Москва, Каширское шоссе, 23

PolynovskiyA. V.ПолыновскийА. В.
Russian Federation

Surgical Department No 3 (Coloproctology), 23 Kashirskoe Shosse, Moscow 115478, Russia

Хирургическое отделение № 3 (онкопроктологии) Минздрава России; Россия, 115478 Москва, Каширское шоссе, 23

RasulovA. O.РасуловА. О.
Russian Federation

Surgical Department No 3 (Coloproctology), 23 Kashirskoe Shosse, Moscow 115478, Russia

Хирургическое отделение № 3 (онкопроктологии) Минздрава России; Россия, 115478 Москва, Каширское шоссе, 23

ФГБУ «Российский онкологический научный центр им. Н. Н. Блохина» Минздрава РоссииN. N. Blokhin Russian Cancer Research Center, Ministry of Health of RussiaФГБУ «Российский онкологический научный центр им. Н. Н. Блохина» Минздрава России100420177146561004201710042017Copyright ©; 2017, ABV-pressCopyright ©; 2017, АБВ-пресс2017ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/203

In 1998, oncologists got a brand new antitumor drug – irinotecan. It’s been already 18 years since its approval for second-line polychemotherapy of metastatic colorectal cancer. Indications for irinotecan use were significantly expanded since that time; it is now used in combination with other therapeutic agents for first- or second-line treatment of metastatic colorectal cancer, in combination with targeted drugs or separately; there are some studies assessing the use of irinotecan in neoadjuvant therapy. The article describes the history and modern schemes of irinotecan administration in treatment of colorectal cancer.

С 1998 г. в арсенале онкологов появился принципиально новый противоопухолевый агент – иринотекан. С момента его одобрения в качестве препарата для проведения 2-й линии полихимиотерапии метастатического колоректального рака прошло уже 18 лет. За это время к применению иринотекана появилось большое количество показаний, его используют в различных сочетаниях с другими препаратами в качестве 1-й и 2-й линий терапии метастатического колоректального рака, в сочетании с таргетными препаратами и без, ведется ряд исследований по изучению работы препарата в неоадъювантном режиме. В статье рассматриваются история и современные схемы применения иринотекана в лечении колоректального рака.

colorectal canceririnotecanfirst-line therapysecond-line therapyколоректальный ракиринотекан1-я линия терапии2-я линия терапии1. Horwitz S. B. Camptothecin. Mehanism of action of antimicrobial and antitumor agents. Eds. by: J. W. Corcoran et al. New York: Springer-Verlag, 1975. Pp. 48–57.Horwitz S. B. Camptothecin. Mehanism of action of antimicrobial and antitumor agents. Eds. by: J. W. Corcoran et al. New York: Springer-Verlag, 1975. Pp. 48–57.2. Hsiang Y. H., Hertzberg R., Hecht S., Liu L. F. Camptothecin induces proteinlinked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260(27):14873–8.Hsiang Y. H., Hertzberg R., Hecht S., Liu L. F. Camptothecin induces proteinlinked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260(27):14873–8.3. Kunimoto T., Nitta K., Tanaka T. et al. Antitumor activity of 7-ethyl-10- [4-(1-piperidino)-1- piperidino] carbonyloxy-camptothecin, a novel watersoluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47(22):5944–7.Kunimoto T., Nitta K., Tanaka T. et al. Antitumor activity of 7-ethyl-10- [4-(1-piperidino)-1- piperidino] carbonyloxy-camptothecin, a novel watersoluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47(22):5944–7.4. Shimada Y., Yoshino M., Wakui A. et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993;11(5):909–13. DOI: 10.1200/JCO.1993.11.5.909.Shimada Y., Yoshino M., Wakui A. et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993;11(5):909–13. DOI: 10.1200/JCO.1993.11.5.909.5. Miller L. L., Locker P. K., Schaaf L. J. et al. Irinotecan hydrochloride (CPT-11, CAMPTOSAR), oncologic drugs advisory committee brochure. New York: Pharmacia & Upjohn, 2000. P. 38. 6. Rothenberg M. L., Eckardt J. R., Kuhn J. G. et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14(4):1128–35. DOI: 10.1200/JCO.1996.14.4.1128.Miller L. L., Locker P. K., Schaaf L. J. et al. Irinotecan hydrochloride (CPT-11, CAMPTOSAR), oncologic drugs advisory committee brochure. New York: Pharmacia & Upjohn, 2000. P. 38. 6. Rothenberg M. L., Eckardt J. R., Kuhn J. G. et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14(4):1128–35. DOI: 10.1200/JCO.1996.14.4.1128.7. Cunningham D., Pyrhonen S., James R. D. et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352(9138):1413–8. DOI: 10.1016/S0140-6736(98)02309-5.Cunningham D., Pyrhonen S., James R. D. et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352(9138):1413–8. DOI: 10.1016/S0140-6736(98)02309-5.8. Cunningham D., Glimelius B. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 1999;26(1 Suppl 5):6–12. PMID: 10213009.Cunningham D., Glimelius B. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 1999;26(1 Suppl 5):6–12. PMID: 10213009.9. Rougier P., Van Cutsem E., Bajetta E. et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352(9138):1407–12. DOI: 10.1016/S0140-6736(98)03085-2. PMID: 9807986.Rougier P., Van Cutsem E., Bajetta E. et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352(9138):1407–12. DOI: 10.1016/S0140-6736(98)03085-2. PMID: 9807986.10. Hosokawa M. Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 2008;13(2):412–31. PMID: 18305428.Hosokawa M. Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 2008;13(2):412–31. PMID: 18305428.11. Kim S. R., Sai K., Tanaka-Kagawa T. et al. Haplotypes and a novel defective allele of CES2 found in a Japanese population. Drug Metab Dispos 2007;35(10):1865–72. DOI: 10.1124/dmd.107.015339. PMID: 17640957.Kim S. R., Sai K., Tanaka-Kagawa T. et al. Haplotypes and a novel defective allele of CES2 found in a Japanese population. Drug Metab Dispos 2007;35(10):1865–72. DOI: 10.1124/dmd.107.015339. PMID: 17640957.12. Mathijssen R. H., van Alphen R. J., Verweij J. et al. Clinical pharmaco kinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7(8):2182–94. PMID: 11489791.Mathijssen R. H., van Alphen R. J., Verweij J. et al. Clinical pharmaco kinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7(8):2182–94. PMID: 11489791.13. Gupta E., Lestingi T. M., Mick R. et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994;54(14): 3723–5. PMID: 8033091.Gupta E., Lestingi T. M., Mick R. et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994;54(14): 3723–5. PMID: 8033091.14. Gupta E., Mick R., Ramirez J. et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997;15(4):1502–10. DOI: 10.1200/JCO.1997.15.4.1502. PMID: 9193346.Gupta E., Mick R., Ramirez J. et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997;15(4):1502–10. DOI: 10.1200/JCO.1997.15.4.1502. PMID: 9193346.15. Gagne J. F., Montminy V., Belanger P. et al. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxy camptothecin (SN-38). Mol Pharmacol 2002;62(3):608–17. PMID: 12181437.Gagne J. F., Montminy V., Belanger P. et al. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxy camptothecin (SN-38). Mol Pharmacol 2002;62(3):608–17. PMID: 12181437.16. Fuchs C. S., Moore M. R., Harker G. et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21(5):807–14. DOI: 10.1200/JCO.2003.08.058. PMID: 12610178.Fuchs C. S., Moore M. R., Harker G. et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21(5):807–14. DOI: 10.1200/JCO.2003.08.058. PMID: 12610178.17. Mullany S., Svingen P. A., Kaufmann S. H., Erlichman C. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycampto thecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 1998;42(5):391–9. DOI: 10.1007/s002800050835. PMID: 9771954.Mullany S., Svingen P. A., Kaufmann S. H., Erlichman C. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycampto thecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 1998;42(5):391–9. DOI: 10.1007/s002800050835. PMID: 9771954.18. Khayat D., Gil-Delgado M., Antoine E. C. et al. European experience with irinotecan plus fluorouracil/folinic acid or mitomycin. Oncology (Williston Park) 1998;12(8 Suppl 6):64–7. PMID: 9726094.Khayat D., Gil-Delgado M., Antoine E. C. et al. European experience with irinotecan plus fluorouracil/folinic acid or mitomycin. Oncology (Williston Park) 1998;12(8 Suppl 6):64–7. PMID: 9726094.19. Andre T., Louvet C., Maindrault-Goebel F. et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuousinfusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35(9):1343–7. PMID: 10658525.Andre T., Louvet C., Maindrault-Goebel F. et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuousinfusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35(9):1343–7. PMID: 10658525.20. Fuchs C. S., Marshall J., Mitchell E. et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25(30):4779–86. DOI: 10.1200/JCO.2007.11.3357. PMID: 17947725.Fuchs C. S., Marshall J., Mitchell E. et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25(30):4779–86. DOI: 10.1200/JCO.2007.11.3357. PMID: 17947725.21. Wulaningsih W., Wardhana A., Watkins J. et al. Irinotecan chemo therapy combined with fluoropyrimi dines versus irinotecan alone for overall survival and progressionfree survival in patients with advanced and/or metastatic colorectal cancer. Cochrane Database Syst Rev 2016;2: CD008593. DOI: 10.1002/14651858.CD008593.pub3.Wulaningsih W., Wardhana A., Watkins J. et al. Irinotecan chemo therapy combined with fluoropyrimi dines versus irinotecan alone for overall survival and progressionfree survival in patients with advanced and/or metastatic colorectal cancer. Cochrane Database Syst Rev 2016;2: CD008593. DOI: 10.1002/14651858.CD008593.pub3.22. Conti J. A., Kemeny N. E., Saltz L. B. et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14(3):709–15. DOI: 10.1200/JCO.1996.14.3.709. PMID: 8622015.Conti J. A., Kemeny N. E., Saltz L. B. et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14(3):709–15. DOI: 10.1200/JCO.1996.14.3.709. PMID: 8622015.23. Vanhoefer U., Harstrick A., Kohne C. H. et al. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemothe rapy in patients with advanced colorectal cancer. J Clin Oncol 1999;17(3):907–13. DOI: 10.1200/JCO.1999.17.3.907. PMID: 10071283.Vanhoefer U., Harstrick A., Kohne C. H. et al. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemothe rapy in patients with advanced colorectal cancer. J Clin Oncol 1999;17(3):907–13. DOI: 10.1200/JCO.1999.17.3.907. PMID: 10071283.24. Ducreux M., Ychou M., Seitz J. F. et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999;17(9):2901–8. DOI: 10.1200/JCO.1999.17.9.2901. PMID: 10561369.Ducreux M., Ychou M., Seitz J. F. et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999;17(9):2901–8. DOI: 10.1200/JCO.1999.17.9.2901. PMID: 10561369.25. Douillard J. Y., Cunningham D., Roth A. D. et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355(9209): 1041–7. PMID: 10744089.Douillard J. Y., Cunningham D., Roth A. D. et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355(9209): 1041–7. PMID: 10744089.26. Maindrault-Goebel F., de Gramont A., Louvet C. et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 2000;11(11): 1477–83. PMID: 11142489.Maindrault-Goebel F., de Gramont A., Louvet C. et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 2000;11(11): 1477–83. PMID: 11142489.27. Maindrault-Goebel F., Louvet C., Andre T. et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35(9):1338–42. PMID: 10658524.Maindrault-Goebel F., Louvet C., Andre T. et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35(9):1338–42. PMID: 10658524.28. Tournigand C., Andre T., Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22(2):229–37. DOI: 10.1200/JCO.2004.05.113. PMID: 14657227.Tournigand C., Andre T., Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22(2):229–37. DOI: 10.1200/JCO.2004.05.113. PMID: 14657227.29. Grothey A., Sargent D., Goldberg R. M., Schmoll H. J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22(7):1209–14. DOI: 10.1200/JCO.2004.11.037. PMID: 15051767.Grothey A., Sargent D., Goldberg R. M., Schmoll H. J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22(7):1209–14. DOI: 10.1200/JCO.2004.11.037. PMID: 15051767.30. Falcone A., Masi G., Allegrini G. et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002;20(19):4006–14. DOI: 10.1200/JCO.2002.12.075. PMID: 12351598.Falcone A., Masi G., Allegrini G. et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002;20(19):4006–14. DOI: 10.1200/JCO.2002.12.075. PMID: 12351598.31. Masi G., Allegrini G., Cupini S. et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 2004;15(12):1766–72. DOI: 10.1093/annonc/mdh470. PMID: 15550581.Masi G., Allegrini G., Cupini S. et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 2004;15(12):1766–72. DOI: 10.1093/annonc/mdh470. PMID: 15550581.32. Falcone A., Ricci S., Brunetti I. et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25(13):1670–6. DOI: 10.1200/JCO.2006.09.0928. PMID: 17470860.Falcone A., Ricci S., Brunetti I. et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25(13):1670–6. DOI: 10.1200/JCO.2006.09.0928. PMID: 17470860.33. Ychou M., Conroy T., Seitz J. F. et al. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 2003;14(3):481–9. PMID: 12598357.Ychou M., Conroy T., Seitz J. F. et al. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 2003;14(3):481–9. PMID: 12598357.34. Ychou M., Viret F., Kramar A. et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with nonresectable liver metastases. Cancer Chemother Pharmacol 2008;62(2):195–201. DOI: 10.1007/s00280-007-0588-3. PMID: 17901955.Ychou M., Viret F., Kramar A. et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with nonresectable liver metastases. Cancer Chemother Pharmacol 2008;62(2):195–201. DOI: 10.1007/s00280-007-0588-3. PMID: 17901955.35. Ychou M., Rivoire M., Thezenas S. et al. FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non- resectable: A phase II randomized study – Prodige – ACCORD 21 (METHEP-2), a unicancer GI trial. 2016 ASCO Annual Meeting. Chicago, 2016.Ychou M., Rivoire M., Thezenas S. et al. FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non- resectable: A phase II randomized study – Prodige – ACCORD 21 (METHEP-2), a unicancer GI trial. 2016 ASCO Annual Meeting. Chicago, 2016.36. Bachet J. B., Lucidarme O., Taïeb J. et al. FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Results of the FFCD 1102 phase II trial. 2016 ASCO Annual Meeting. Chicago, 2016.Bachet J. B., Lucidarme O., Taïeb J. et al. FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Results of the FFCD 1102 phase II trial. 2016 ASCO Annual Meeting. Chicago, 2016.37. Martin R. C., Joshi J., Robbins K. et al. Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol 2009;2009:539795. DOI: 10.1155/2009/539795.Martin R. C., Joshi J., Robbins K. et al. Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol 2009;2009:539795. DOI: 10.1155/2009/539795.38. Martin R. C. 2nd, Scoggins C. R., Schreeder M. et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 2015;121(20):3649–58. DOI: 10.1002/cncr.29534.Martin R. C. 2nd, Scoggins C. R., Schreeder M. et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 2015;121(20):3649–58. DOI: 10.1002/cncr.29534.39. Van Cutsem E., Kohne C. H., Hitre E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408–17. DOI: 10.1056/NEJMoa0805019.Van Cutsem E., Kohne C. H., Hitre E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408–17. DOI: 10.1056/NEJMoa0805019.40. Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23):2335–42. DOI: 10.1056/NEJMoa032691. PMID: 15175435.Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23):2335–42. DOI: 10.1056/NEJMoa032691. PMID: 15175435.41. Heinemann V., von Weikersthal L. F., Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as firstline treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15(10):1065–75. DOI: 10.1016/S1470-2045(14)70330-4.Heinemann V., von Weikersthal L. F., Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as firstline treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15(10):1065–75. DOI: 10.1016/S1470-2045(14)70330-4.42. Saltz L. B., Kanowitz J., Kemeny N. E. et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996;14(11):2959–67. DOI: 10.1200/JCO.1996.14.11.2959. PMID: 8918493.Saltz L. B., Kanowitz J., Kemeny N. E. et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996;14(11):2959–67. DOI: 10.1200/JCO.1996.14.11.2959. PMID: 8918493.43. Saltz L. B., Cox J. V., Blanke C. et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343(13):905–14. DOI: 10.1056/NEJM200009283431302. PMID: 11006366.Saltz L. B., Cox J. V., Blanke C. et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343(13):905–14. DOI: 10.1056/NEJM200009283431302. PMID: 11006366.44. Rougier P., Lepille D., Bennouna J. et al. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Ann Oncol 2002;13(10):1558–67. PMID: 12377643.Rougier P., Lepille D., Bennouna J. et al. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Ann Oncol 2002;13(10):1558–67. PMID: 12377643.45. Grothey A., Jordan K., Kellner O. et al. Capecitabine/irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: Results of a randomized phase II study. J Clin Oncol 2004;22(14 Suppl):3534.Grothey A., Jordan K., Kellner O. et al. Capecitabine/irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: Results of a randomized phase II study. J Clin Oncol 2004;22(14 Suppl):3534.46. Seymour M. T. Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): A 2135- patient randomized trial in advanced colorectal cancer (ACRC). J Clin Oncol 2005;23(90160):3518.Seymour M. T. Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): A 2135- patient randomized trial in advanced colorectal cancer (ACRC). J Clin Oncol 2005;23(90160):3518.47. Pluzanska A., Mainwaring P., Cassidy J. et al. Final results of a rando mized phase III study evaluating the addition of oxaliplatin first line to 5-FU followed by irinotecan at progression in advanced colorectal cancer (LIFE study). J Clin Oncol 2005;23(90160):3517.Pluzanska A., Mainwaring P., Cassidy J. et al. Final results of a rando mized phase III study evaluating the addition of oxaliplatin first line to 5-FU followed by irinotecan at progression in advanced colorectal cancer (LIFE study). J Clin Oncol 2005;23(90160):3517.48. Sobrero A. F., Maurel J., Fehrenbacher L. et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(14):2311–9. DOI: 10.1200/JCO.2007.13.1193.Sobrero A. F., Maurel J., Fehrenbacher L. et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(14):2311–9. DOI: 10.1200/JCO.2007.13.1193.49. Van Cutsem E., Tabernero J., Lakomy R. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499–506. DOI: 10.1200/JCO.2012.42.8201. PMID: 22949147.Van Cutsem E., Tabernero J., Lakomy R. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499–506. DOI: 10.1200/JCO.2012.42.8201. PMID: 22949147.50. Tabernero J., Yoshino T., Cohn A. L. et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoro pyrimidine (RAISE): a randomised, double-blind, multicentre, phase III study. Lancet Oncol 2015;16(5):499–508. DOI: 10.1016/S1470-2045(15)70127-0.Tabernero J., Yoshino T., Cohn A. L. et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoro pyrimidine (RAISE): a randomised, double-blind, multicentre, phase III study. Lancet Oncol 2015;16(5):499–508. DOI: 10.1016/S1470-2045(15)70127-0.51. Cunningham D., Humblet Y., Siena S. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337–45. DOI: 10.1056/NEJMoa033025. PMID: 15269313.Cunningham D., Humblet Y., Siena S. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337–45. DOI: 10.1056/NEJMoa033025. PMID: 15269313.52. Rougier P., Raoul J.-L., Van Laethem J.-L. et al. Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal CA. 2004.Rougier P., Raoul J.-L., Van Laethem J.-L. et al. Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal CA. 2004.53. Folprecht G., Lutz M. P., Schoffski P. et al. Cetuximab and irinotecan/5-fluorouracil/ folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17(3):450–6. DOI: 10.1093/annonc/mdj084. PMID: 16303861.Folprecht G., Lutz M. P., Schoffski P. et al. Cetuximab and irinotecan/5-fluorouracil/ folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17(3):450–6. DOI: 10.1093/annonc/mdj084. PMID: 16303861.54. Van Cutsem E., Kohne C. H., Lang I. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29(15):2011–9. DOI: 10.1200/JCO.2010.33.5091.Van Cutsem E., Kohne C. H., Lang I. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29(15):2011–9. DOI: 10.1200/JCO.2010.33.5091.55. Giantonio B. J., Catalano P. J., Meropol N. J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539–44. DOI: 10.1200/JCO.2006.09.6305. PMID: 17442997.Giantonio B. J., Catalano P. J., Meropol N. J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539–44. DOI: 10.1200/JCO.2006.09.6305. PMID: 17442997.56. Lenz H.-J., Lee F.-C., Yau L. et al. MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status. 2016 ASCO AnnualLenz H.-J., Lee F.-C., Yau L. et al. MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status. 2016 ASCO AnnualMeeting. Chicago, 2016.57. Peeters M., Price T. J., Cervantes A. et al. Final results from a randomized phase 3 study of FOLFIRI {+/–} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25(1):107–16. DOI: 10.1093/annonc/mdt523.Peeters M., Price T. J., Cervantes A. et al. Final results from a randomized phase 3 study of FOLFIRI {+/–} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25(1):107–16. DOI: 10.1093/annonc/mdt523.58. Peeters M., Price T. J., Cervantes A. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28(31):4706–13. DOI: 10.1200/JCO.2009.27.6055.Peeters M., Price T. J., Cervantes A. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28(31):4706–13. DOI: 10.1200/JCO.2009.27.6055.59. Chibaudel B., Bonnetain F., Tournigand C. et al. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. BMC Cancer 2015;15:496. DOI: 10.1186/s12885-015-1503-7.Chibaudel B., Bonnetain F., Tournigand C. et al. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. BMC Cancer 2015;15:496. DOI: 10.1186/s12885-015-1503-7.60. Klautke G., Kuchenmeister U., Foitzik T. et al. Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer 2006;94(7):976–81. DOI: 10.1038/sj.bjc.6603053.Klautke G., Kuchenmeister U., Foitzik T. et al. Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer 2006;94(7):976–81. DOI: 10.1038/sj.bjc.6603053.61. Klautke G., Küchenmeister U., Foitzik T. et al. Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: Four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response. Radiother Oncol 1985;(3):379–84. DOI: 10.1016/j.radonc.2007.10.042. PMID: 18036687.Klautke G., Küchenmeister U., Foitzik T. et al. Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: Four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response. Radiother Oncol 1985;(3):379–84. DOI: 10.1016/j.radonc.2007.10.042. PMID: 18036687.62. Willeke F., Horisberger K., Kraus-Tiefenbacher U. et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer 2007;96(6):912–7. DOI: 10.1038/sj.bjc.6603645.Willeke F., Horisberger K., Kraus-Tiefenbacher U. et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer 2007;96(6):912–7. DOI: 10.1038/sj.bjc.6603645.63. Gollins S., Sun Myint A., Haylock B. et al. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes. J Clin Oncol 2011;29(8):1042–9. DOI: 10.1200/JCO.2010.29.7697.Gollins S., Sun Myint A., Haylock B. et al. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes. J Clin Oncol 2011;29(8):1042–9. DOI: 10.1200/JCO.2010.29.7697.64. Jung M., Shin S. J., Koom W. S. et al. A randomized phase II study of neoadjuvant chemoradiaton therapy with 5-fluorouracil/leucovorin or irinotecan/S-1 in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2015;93(5):1015–22. DOI: 10.1016/j.ijrobp.2015.08.037.Jung M., Shin S. J., Koom W. S. et al. A randomized phase II study of neoadjuvant chemoradiaton therapy with 5-fluorouracil/leucovorin or irinotecan/S-1 in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2015;93(5):1015–22. DOI: 10.1016/j.ijrobp.2015.08.037.65. Sato T., Kokuba Y., Koizumi W. et al. Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007;69(5):1442–7. DOI: 10.1016/j.ijrobp.2007.05.081. PMID: 17855009.Sato T., Kokuba Y., Koizumi W. et al. Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007;69(5):1442–7. DOI: 10.1016/j.ijrobp.2007.05.081. PMID: 17855009.66. Sato T., Ozawa H., Hatate K. et al. A phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. Int J Radiat Oncol Biol Phys 2011;79(3):677–83. DOI: 10.1016/j.ijrobp.2009.11.007.Sato T., Ozawa H., Hatate K. et al. A phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. Int J Radiat Oncol Biol Phys 2011;79(3):677–83. DOI: 10.1016/j.ijrobp.2009.11.007.67. Nakamura T., Yamashita K., Sato T. et al. Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors. Int J Radiat Oncol Biol Phys 2014;89(3):547–55. DOI: 10.1016/j.ijrobp.2014.03.007.Nakamura T., Yamashita K., Sato T. et al. Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors. Int J Radiat Oncol Biol Phys 2014;89(3):547–55. DOI: 10.1016/j.ijrobp.2014.03.007.68. Saltz L. B., Niedzwiecki D., Hollis D. et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007;25(23):3456–61. DOI: 10.1200/JCO.2007.11.2144. PMID: 17687149.Saltz L. B., Niedzwiecki D., Hollis D. et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007;25(23):3456–61. DOI: 10.1200/JCO.2007.11.2144. PMID: 17687149.69. Van Cutsem E., Labianca R., Bodoky G. et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27(19):3117–25. DOI: 10.1200/JCO.2008.21.6663.Van Cutsem E., Labianca R., Bodoky G. et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27(19):3117–25. DOI: 10.1200/JCO.2008.21.6663.70. Ychou M., Raoul J. L., Douillard J. Y. et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009;20(4):674–80. DOI: 10.1093/annonc/mdn680.Ychou M., Raoul J. L., Douillard J. Y. et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009;20(4):674–80. DOI: 10.1093/annonc/mdn680.71. Masi G., Lonardi S., Sainato A. et al. Results of the phase II TRUST trial of induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemoradiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC). 2016 ASCO Annual Meeting. Chicago, 2016.Masi G., Lonardi S., Sainato A. et al. Results of the phase II TRUST trial of induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemoradiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC). 2016 ASCO Annual Meeting. Chicago, 2016.72. Wasserman E., Cuvier C., Lokiec F. et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1999;17(6):1751–9. DOI: 10.1200/JCO.1999. 17.6.1751. PMID: 10561212.Wasserman E., Cuvier C., Lokiec F. et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1999;17(6):1751–9. DOI: 10.1200/JCO.1999. 17.6.1751. PMID: 10561212.73. Goldberg R. M., Sargent D. J., Morton R. F. et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22(1):23–30. DOI: 10.1200/JCO.1999.17.6.1751. PMID: 10561212.Goldberg R. M., Sargent D. J., Morton R. F. et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22(1):23–30. DOI: 10.1200/JCO.1999.17.6.1751. PMID: 10561212.74. Fischer von Weikersthal L., Schalhorn A., Stauch M. et al. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. Eur J Cancer 2011;47(2):206–14. DOI: 10.1016/j.ejca.2010.09.022.Fischer von Weikersthal L., Schalhorn A., Stauch M. et al. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. Eur J Cancer 2011;47(2):206–14. DOI: 10.1016/j.ejca.2010.09.022.75. Sgouros J., Aravantinos G., Dragasis S. et al. Reintroduction of irinotecan and oxaliplatin as a combination (IROX regimen) in heavily pretreated colorectal cancer patients – A single- center experience. Forum Clin Oncol 2013;4(3):13–8.Sgouros J., Aravantinos G., Dragasis S. et al. Reintroduction of irinotecan and oxaliplatin as a combination (IROX regimen) in heavily pretreated colorectal cancer patients – A single- center experience. Forum Clin Oncol 2013;4(3):13–8.